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ABSTRACT 
We aimed to investigate the natural killer (NK) cell activity in 
hGH-deficient adults and to analyze the effect of insulin-like growth 
factor (IGF)-I in uivo and in vitro on NK cell activity. NK cell activity 
was measured in a 4-h nonisotopic assay with europium-labeled and 
cryopreserved K-562 cells. NK-cell numbers were measured after 
incubation with murine monoclonal CD3 and CD16 antibodies by flow 
cytometry analysis. In a cross-sectional study, the basal and inter- 
feron-p (IFN-P) stimulated (1000 IU/ml) NK cell activity of 15 hGH- 
deficient patients and 15 age- and sex-matched controls was mea- 
sured. The percentages and absolute numbers of CD3./16+ NK-cells 
were not significantly different in the patient vs. control group. The 
basal and IFN-P stimulated NK cell activity however was signifi- 
cantly decreased in the patient vs. control group at all effecter/target 
(E/T) cell ratios from 12.5-100 (e.g. 17 ? 3 vs. 28 ? 3% lysis without 
IFN-P, P < 0.05, and 42 t 4 vs. 57 2 4% lysis with IFN-0, P < 0.05; 
both at E/T 50). IGF-I levels of patients and controls showed a sig- 
nificant positive correlation with NK cell activity (r = 0.37; P < 0.05). 
In an IGF-I in vitro study (IGF-I in vitro 250-1250 kg/L), the basal and 
IFN-P stimulated NK cell activity of 13 hGH-deficient patients and of 
18 normal subjects was significantly enhanced by IGF-I in vitro (e.g. 
GH-deficient patients: 9 ? 2 us. 10 2 2% lysis without IFN-P, P < 0.05 
and 25 + 4 vs. 30 + 4% lysis with IFN-/3, P < 0.005; and normal 
subjects: 15 + 3 vs. 23 ? 3% lysis without IFN-/3, P < 0.001 and 35 2 
4 us. 44 + 5% lysis with IFN-P, P < 0.001; both at IGF-I 500 pg/L). 
In summary, in our cross-sectional study, adult GH-deficient patients 
showed a significantly lower basal and IFN-P stimulated NK cell 
activity than matched controls, despite equal NK cell numbers. IGF-I 
levels of patients and controls showed a weak positive correlation with 
NK cell activity. In an in vitro study, IGF-I significantly enhanced 
basal and IFN-P stimulated NK cell activity of hGH-deficient patients 
and also of normal subjects. The decreased NK cell activity in GH- 
deficient patients may be caused at least in part by low serum IGF-I 
levels. IGF-I appears to be an independent coregulatory modulator of 
NK cell activity. (Endocrinology 137: 5332-5336, 1996) 
R ECENTLY, HUMAN GH and insulin-like growth fac- tor(IGF)-I have been shown to play an important role 
in the cellular and humoral immune system (l-4). hGH and 
IGF-I receptors have been found on different human lym- 
phocyte subsets including natural killer (NK) cells (5-7). 
Natural killer cells are CD3-CD16+ peripheral lymphocytes, 
mediating non-MHC-restricted cytotoxicity, which can be 
stimulated by IFN-(Y, IFN-/3, and IL-Z (8-10). Decreased NK 
cell activity in hGH-deficient children was first observed by 
Kiess et al. (ll), and short-term GHRH substitution therapy 
was reported to have no effect on NK cell activity (12). Other 
studies also found a decreased NK cell activity in hGH- 
deficient patients and reported an increase of NK cell activity 
during hGH substitution therapy (13,14). In viuo IGF-I serum 
levels were reported to show a weak positive correlation with 
NK cell activity (14). In vitro IGF-I was reported to stimulate 
basal NK cell activity (6). Recently Watanabe et al. (15) have 
suggested an increased risk of leukemia in GH-deficient chil- 
dren and have hypothesized the reduced NK cell activity in 
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GH-deficiency being one possible explanation for this 
phenomenon. 
We aimed to investigate the effect of hGH-deficiency on 
NK cell activity in adult patients in comparison to age- and 
sex-matched controls. After showing a significant correlation 
between serum levels of IGF-I and NK cell activity, we also 
aimed to investigate the effects of IGF-I in vitro on NK cell 
activity of hGH-deficient adult patients and normal subjects. 
Materials and Methods 
Subjects 
In the cross-sectional study, 15 hGH-deficient adult patients and 15 
age- and sex-matched controls were enrolled. GH-deficiency in the pa- 
tients was defined by GH serum levels below 2.0 *g/liter during insulin 
tolerance test or arginin stimulation test and concomitant subnormal 
IGF-I levels as compared with the age-related reference range. The 
hGH-deficient patients were of adult (n = 12) or childhood (n = 3) onset 
and had different etiologies causing their hGH-deficiency: pituitary 
inactive adenoma (n = 4), prolactinoma (n = 2), craniopharyngeoma 
(n = 3), septo optic dysplasia (n = 1), Sheehan syndrome (n = l), and 
idiopathic isolated childhood onset hGH-deficiency (n = l), as well as 
3 unexplained panhypopituitarisms, suspected to be pqst-traumatic. In 
12 out of 15 of the patients in whom GH-deficiency was combined with 
impairment of other pituitary functions, adequate substitution therapy 
was performed with hydrocortisone (n = S), T, (n = 9), sex steroids (n = 
12), and vasopressin analogs (n = 3), respectively. Controls were care- 
fully matched for age (37 f 3 US. 39 + 3 yr; mean ? SE), sex (5 females 
and 10 males in each group), and body weight (76 ? 4 VS. 76 ? 3 kg) to 
the patients. The patient group showed significantly lower basal serum 
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levels of GH (0.3 + 0.1 US. 2.4 i- 0.9 pg/liter; P < 0.05), IGF-I (66 t 12 
us. 159 + 12 kg/liter; P < O.OOl), and IGFBP-3 (2175 -C 306 US. 3558 i- 
184 wg/liter; P < 0.01). Serum levels of free T4 and free T3 as well as PRL 
did not differ significantly between the patients and control group. 
Blood drawing and determination of NK cell number and NK cell 
activity were performed on the same day for each patient and matched 
control subject. 
In the IGF-I iif ilitrn study, NK cell activity of 13 hGH-deficient pa- 
tients (sex: 6 female and 7 male; age: 45 2 4 yr; IGF-I: 40 ? 7 pg/liter) 
and 18 normal subjects (sex: 9 female and 9 male; age: 48 2 6 yr; IGF-I: 
168 + 23 pg/liter) was investigated without and with addition of IGF-I 
irl nitro. Also in this study, GH-deficiency was defined by the above 
mentioned criteria. 
Blood samples were obtained from patients and controls after written 
informed consent. 
Materials 
RPM1 1640 medium with HEPES and fetal calf serum were purchased 
from GIBCO, Paisely, Scotland. Human AB serum, HEPES, DMSO, and 
Triton-X 100 were from Sigma, St. Louis, MO. Ficoll separating solution, 
RPM1 1640 medium without HEPES, glutamine, penicillin/streptomy- 
cin and amphotericin B were purchased from Seromed, Berlin, Germany. 
NaCI, KCI, MgCl,, CaC&, glucose, and DTPA were purchased from 
Merck, Darmstadt, Germany. Dextrane sulphate was from Pharmacia, 
Uppsala, Sweden. Murine anti CD3 and anti CD16 monoclonal anti- 
bodies were from Dianova, Hamburg, Germany. The lysis and fixation 
solution for flow cytometry were from Coulter, Krefeld, Germany. Eu- 
ropium was from Aldrich, Milwaukee, WI. V-shaped 96.well plates were 
from Greiner, Frickenhausen, Germany. Flat-bottom 96.well hlates were 
from Nunc. Roskilde. Denmark. Recombinant (r)hIGF-I was obtained 
from GroPep, Adelaide, Australia. Recombinant human interferon-p 
was from Rentschler, Laupheim, Germany. Europium time-resolved 
fluorescence was measured in a 1232 DELFIA fluorometer. This flu- 
orometer as well as Europium enhancement solution, which trans-che- 
lates Europium-ions into a highly fluorescent complex, were from Wal- 
lac, Turku, Finland. The IGF-I RIA was purchased from Biomerieux, 
Niirtlingen, Germany. Goat antihuman IGFBP-3 antibodies were from 
Diagnostic Systems Laboratories, Webster, TX. 
Lymphocyte preparation from peripheral blood 
Lymphocyte preparation from peripheral blood was performed by 
the Isopaque-Ficoll technique as described by Boyum (16). Briefly, pe- 
rioheral whole blood was diluted with assav medium (RPM1 1640 me- 
d;um with 25 rnM HEPES, supplemented wjth 1% human AB serum, 2 
mM glutamine, penicillin/streptomycin and amphotericin B) and lay- 
ered over Isopaque-Ficoll. After centrifugation at 1200 g for 20 min, the 
interface region was carefully removed with a pipette. Peripheral blood 
mononuclear cells (PBMC) were washed twice with assay medium and 
centrifuged at 600 g for 8 min. PBMC were adjusted to 1 X 107cells/ml, 
and viability was determined by trypan blue staining and was normally 
higher than 95%. 
Measurement of NK cell numbers 
Lymphocyte subset measurement was performed by incubation of 50 
~1 EDTA blood with 20 ~1 of FITC- and PE-labeled specific murine 
monoclonal antibodies against CD3 and CD16 antigens for 30 min. Red 
blood cell lysis and fixation of the sample was done by an automatic 
cycler. Flow cytometry scan analysis was performed on an EPICS I 
(Coulter, Krefeld, Germany). The analysis was routinely performed on 
the day of blood collection. 
Labeling of K-562 cells with europium 
NK cell activity was measured in a 4-h nonisotopic assay with eu- 
ropium-labeled and cryopreserved K-562 cells, as recently described by 
Blomberg ct nl. (17, 18) and Maley et 01. (19). Briefly, K-562 cells (ATCC 
no. CCL243) were grown in culture medium (RPM1 1640 medium with- 
out HEPES, supplemented with 10% FCS, 2 mM glutamine, penicillin/ 
streptomycin and amphotericin B). For labeling, cells were washed with 
HEPES buffer (50 mM HEPES, 93 mM NaCl, 5 mM KCI, 2 mM MgCI,, pH 
7.4). 5 X 10’ K-562 cells were incubated with 10 ml of labeling buffer 
(HEPES buffer containing 100 WM europium, 2 mM DTPA, and 500 PM 
dextran sulphate) for 12 min at 37 C, while cells were gently suspended 
every 3 min. Then, 10 ml repairing buffer (HEPES buffer containing 2 
mM CaCI, and 10 mM glucose) were added, and incubation was con- 
tinued for 3 min. After centrifugation, cells were washed once more with 
repairing buffer and another four times with RPM1 1640 medium. Cells 
were resuspended in ice-cold RPM1 1640 medium containing 15% FCS 
and 10% DMSO, and 5 X 10” to 1 X lo7 labeled K-562 cells were aliquoted 
per vial. The vials were slowly frozen to -80 C with the help of a 
cryo-box containing isopropanol and then transferred to the liquid ni- 
trogen storage. 
Measurement of NK cell activity 
For performance of NK cell activity assay, one vial containing eu- 
ropium-labeled and cryopreserved K-562 (Eu-K-562) cells was thawed 
auicklv at 37 C, and cells were washed twice with RPM1 1640 medium 
without HEPES, supplemented with 1% human AB serum, 2 mM glu- 
tamine, penicillin/streptomycin, and amphotericin B. Cells were ad- 
justed to 2 X lll~cells/ml, and viability was determined by trypan blue 
staining and was normally higher than 95%. Viable Eu-K-562 cells were 
pipetted into 96.well v-shaped plates at 10” cells per well. 12.5 X lo“, 
25 X lo”, 50 X lo”, and 100 X 10” PBMC were pipetted per well, 
corresponding to E/T ratios of 12.5,25,50, and 100. IFN-f3 or IGF-I were 
added in volumes of 10 ~1. Incubation was performed in a humidified 
incubator for 4 h at 37 C and 5% C02. Then, plates were centrifuged at 
400 g for 5 min, and 20 ~1 of supernatant was transferred to a flat-bottom 
96.well plate. 200 ~1 of enhancement solution was added per well, and 
plates were incubated for 5 min while gently shaking. Then, time re- 
solved fluorescence was measured in a 1232 Delfia fluorometer. NK cell 
activity was calculated as % lysis = (maximal release - spontaneous 
release)/ (experimental release - spontaneous release). For the mea- 
surement of the spontaneous release, Eu-K-562 cells were incubated 
without PBMC. For the measurement of the maximal release, Eu-K-562 
cells were incubated with 0.5% Triton-X 100. The spontaneous release of 
europium-labeled and cryopreserved K-562 cells was 38,000 + 2,000 
counts (29 ? l%), while the maximal release was 129,000 2 5,000 counts, 
thus yielding a broad dynamic range of approximately 90,000 counts for 
reliable measurement of NK cell activity. 
Assays of IGF-I and IGFBP-3 
IGF-I was measured by a commercial RIA using IGFBP saturation by 
IGF-II (20). Intra- and interassay coefficients of variation were less than 
4.0% and less than 7.0% over the entire assay range, respectively. The 
reference range of 90-350 Kg/liter was established for adults between 
25-60 yr of age by calculation of the 5th and 95th percentile of the results 
from 304 healthy volunteers. 
IGFBP-3 was measured by a sandwich-type assay using polyclonal 
goat antihuman IGFBP-3 antibodies as published previously (21). Intra- 
and interassay coefficients of variation were both less than 6.0% over the 
entire assay range, respectively. The reference range of 2000-5200 Fg/ 
liter was established for adults between 25-60 yr of age by calculation 
of the 5th and 95th percentile of the results from 295 healthy volunteers. 
IGF-I in vitro study 
rhIGF-I was dissolved in RPM1 1640 medium, and 10 ~1 of different 
concentrations were added per well. The final IGF-I concentrations per 
well, assayed by a specific IGF-I assay as described above, were 250,500, 
and 1250 kg/liter. 
Statistical analysis 
In the cross-sectional study statistical comparison between the GH- 
deficient patients and the age- and sex-matched controls was performed 
by the Mann-Whitney U test. In the IGF-I irr oitro study comparison 
between the NK cell activity without and with addition of IGF-I itr vitro 
was performed by the Wilcoxon signed rank test. Probability of less than 
0.05 was considered significant. All data are shown as the mean + SE 
unless otherwise noted. 
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FIG. 1. Basal (A) and IFN-P (B) stimulated NK cell activity in GH- 
deficient patients and age- and sex-matched controls. A, The basal NK 
cell activity was significantly reduced in GH-deficient patients in 
comparison with age- and sex-matched controls at all effectorkarget 
cell ratios (E/T). *, P i 0.05; *‘@, P < 0.01. B, The IFN-p stimulated 
NK cell activity was significantly reduced in GH-deficient patients in 
comparison with age- and sex-matched controls at all effectorkarget 
cell ratios (E/T). *, P < 0.05. 
Results 
Cross-sectional in vivo study 
Total lymphocyte numbers (2.239 k 0.199 ~-IS. 2.020 -t 0.170 
g/liter) as well as the percentage and absolute number of 
CD33/CD16+ NK cells (9 t 2 ~1s. 11 + 2% and 0.195 + 0.032 
us. 0.222 k 0.051 G/L) did not differ significantly between the 
hGH-deficient patients and controls. 
The basal as well as the IFN-/3 stimulated NK cell activity 
were significantly lower in hGH-deficient patients than in 
age- and sex-matched controls at all tested effector-target cell 
ratios from 12.5-100 (Fig. 1). However, stimulation with 
IFN-/3 caused an increase of NK cell activity in both groups, 
and the absolute increase from basal to IFN-P stimulated NK 
cell activity was not signficantly different in the hGH-defi- 
cient patients 11s. the age- and sex-matched controls. 
In the combined analysis of adult hGH-deficient patients 
and age- and sex-matched controls, Pearsson’s correlation 
performed after assuring normal distribution of data (Kol- 
mogorov-Smirnov test P > 0.10) revealed a positive associ- 
ation of IGF-I levels with summarized basal and IFN-/3 stim- 
ulated NK cell activity, which was significant (R = 0.37; P < 
0.05; Fig. 2). 
IGF-I in vitro study 
In 18 normal subjects IGF-I in z~jtro at final concentrations 
of 250,500, and 1250 pg/liter caused a significant increase of 
basal NK cell activity (14 k 3% without IGF-I us. 20 ‘- 3,23 -t 
3, and 22 + 3% lysis, P < 0.01). IFN-P stimulated NK cell 
activity was also significantly increased by IGF-I in vitro (35 2 
500 - r = 0.37; pcO.05 
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FIG. 2. Association of serum IGF-I levels with the summarized NK 
cell activity of GH-deficient patients and sex- and age-matched con- 
trols. 
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FIG. 3. Effect of IGF-I in vitro on basal and IFN-p stimulated NK cell 
activity in normal subjects. A, The basal and IFN-P stimulated NK 
cell activity of normal subjects was significantly increased by IGF-I 
in vitro at 250, 500, and 1250 pg/Iiter. **, P < 0.01; ***, P i 0.001. 
B, The increase of the basal and IFN-P stimulated NK cell activity of 
single normal subjects by IGF-I in vitro at 500 fig/liter. 
4% without IGF-I us. 43 k 4, 44 k 5, and 45 + 5% lysis, P < 
0.001) (Fig. 3). 
In 13 hGH-deficient adult patients, IGF-I in vitro at final 
concentrations of 250, 500, and 1250 pg/liter also caused a 
small but significant increase of basal NK cell activity (9 2 
2% without IGF-I vs. 10 2 2, ns., 10 2 2, and 11 2 2% lysis, 
P < 0.05). IFN-0 stimulated NK cell activity was also sig- 
nificantly increased by IGF-I in vitro (25 2 4% without IGF-I 
vs. 30 + 4, 30 2 4, and 30 C 4% lysis, P < 0.01) (Fig. 4). 
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FIG. 4. Effect of IGF-I in vitro on basal and IFN-p stimulated NK cell 
activity in GH-deficient patients. A, The basal and IFN-/3 stimulated 
NK cell activity of GH-deficient patients was significantly increased 
by IGF-I in vitro at 250, 500, and 1250 kg/liter-:“, P < 0.05; :*:I’, P < 
0.01. B) The increase of the basal and IFN-B stimulated NK cell 
activity of single GH-deficient patients by IGE-I in vitro at 500 pg/ 
liter. 
Discussion 
We have shown that the NK cell activity is significantly 
decreased in hGH-deficient adult patients in comparison 
with age- and sex-matched controls despite comparable and 
normal NK cell numbers. These results are in agreement with 
several studies on hGH-deficient children describing a de- 
creased NK cell activity despite normal NK cell numbers 
(11-13). In hGH-deficient children, NK cell activity has been 
shown to increase during hGH replacement therapy (13). We 
have also shown that in a combined analysis of hGH-defi- 
cient adult patients and age- and sex-matched controls to- 
gether, the serum IGF-I level correlates significantly with NK 
cell activity. This analysis was performed after assuring nor- 
mal distribution of data in both datasets by Kolmogorov- 
Smirnov test. This finding is in agreement with a study from 
Crist et nl. (14), who reported a similar correlation between 
serum IGF-I levels and NK cell activity in women with im- 
paired endogenous GH secretion. We observed no signifi- 
cant correlation between IGFBP-3 serum levels and NK cell 
activity (data not shown). However, in adults IGFBP-3 in 
comparison to IGF-I has been reported to be a rather weak 
parameter for the assessment of the GH secretory status (22, 
23). Therefore, we believe that finding no association be- 
tween IGFBP-3 and NK cell activity is caused by the poor 
reflection of the GH-secretory-status by IGFBP-3. To the best 
of our knowledge there do not exist any data on the in vitro 
effects of GH on NK cell activity or NK number. As IGF-I and 
GH-receptors have both been demonstrated to exist on NK 
cells (5-7), in addition to the described effects of IGF-I on NK 
cell activity, GH may directly play a role in modulating NK 
cell activity. 
In our cross-sectional study of hGH-deficient adult pa- 
tients the NK cell activity was found to be increased by 
stimulation with 1000 III/ml IFN-/3 in vitro to the same extent 
as in age- and sex-matched controls. These results are in 
contrast to the findings of Kiess et al. (12), who reported NK 
cell activity of hGH-deficient children not to be stimulated by 
1500 IU/ml IFN-a in vitro and hypothesized a functional 
defect of NK cells of hGH-deficient children. These different 
results might be explained in part by the use of different 
stimulatory agents and different assay systems in the two 
studies. We used europium-labeled K-562 cells, which are 
known to have a shorter lag period of marker release and a 
higher marker release than 51Cr-labeled K-562 cells (18). In 
contrast, Kiess et al. used 75Se-methionine- or 51Cr-labeled 
K-562 cells, which show a much lower marker release than 
the europium-labeled K-562 cells we used. Therfore, Kiess et 
al. might have missed an increase of NK cell activity in 
hGH-deficient children by IFN-ol in vitro, because the assay 
system used was not sensitive enough to measure a small 
increase of NK cell activity from very low basal values. By 
contrast, our assay system enabled us to measure NK cell 
activity over a broad dynamic range of lysis, and we thus 
may have been able to show an increase of NK cell activity 
by IFN-/3, despite low basal NK cell activity in the hGH- 
deficient adult patients group. The use of IFN-P instead of 
IFN-ol as used in the study of Kiess et al. must also be con- 
sidered, although both interferons have been described as 
very potent stimulators of NK cell activity (8). Our findings 
show an adequate stimulation of NK cell activity of hGH- 
deficient adult patients and do not indicate a functional de- 
fect of NK cells in hGH-deficient adult patients. 
Prompted by our observation of a positive association 
between IGF-I serum levels and NK cell activity, we studied 
the effect of IGF-I in vitro on NK-cell activity. In accordance 
with the results published by Kooijman et al. (6), we dem- 
onstrated that basal NK cell activity of normal subjects can 
be increased by IGF-I in vitro. In addition, we also found 
IFN-/3 stimulated NK cell activity to be further increased by 
IGF-I in vitro. Using IGF-I in vitro in concentrations of 250 
pg/liter, 500 pLg/ liter, and 1250 pg/liter we could not find 
a clear dose-response relationship between IGF-I and NK cell 
activity. In serum most of IGFs are bound to IGFBPs (24), 
whereas in our assay system, by incubating isolated PMNCs 
in medium containing only 1% human AB serum, a high 
percentage of “free” IGF-I may have been present. Thus, 
using probably supraphysiological concentrations of IGF-I in 
our assay system, we observed almost maximal stimulation 
of NK cell activity by the lowest concentration of IGF-I tested 
(250 pg/liter). Further studies therefore should use lower, 
more physiological concentrations of “free” IGF-I. 
IFN-/3 and IGF-I in vitro appear to have an independent, 
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additive effect on NK cell activity. IFN-P in vitro has been 
reported not to affect the levels of GH mRNA in NK cells, and 
GH has been found not to induce IFN production (25). To the 
best of our knowledge, similar data on possible interactions 
of IGF-I and IFN do not exist. 
Furthermore, we were able to demonstrate, that IGF-I in 
vitro can increase the basal and IFN-/3 stimulated NK cell 
activity of hGH-deficient adult patients. The increase of basal 
NK cell activity in hGH-deficient adult patients by IGF-I in 
vitro, although statistically significant, was very small. This 
may be caused by the low basal NK cell activity of hGH- 
deficient adult patients being close to the lower detection 
limit of the NK assay system. At the higher IFN-/3 stimulated 
NK cell activities in hGH-deficient patients, however, we 
could demonstrate a profound increase of NK cell activity by 
IGF-I in vitro. These in vifro data and the data on the positive 
association between serum IGF-I levels and NK cell activity 
indicate that NK cell activity in hGH-deficient patients might 
be decreased because of lower serum levels of IGF-I, and NK 
cell activity can be increased by elevating the IGF-I serum 
levels. However, an additional direct effect of GH on NK cell 
activity, teleologically hypothesized because of GH receptor 
expression on NK cells, still remains to be demonstrated. 
In summary, basal and IFN-/3 stimulated NK cell activity was 
found to be decreased in hGH-deficient adult patients in com- 
parison to age- and sex-matched controls, despite equal NK cell 
numbers. NK cell activity was stimulated by IFN-P in hGH- 
deficient adult patients and in age- and sex-matched controls, 
indicating that there does not exist a functional defect of the NK 
cells in hGH-deficient adult patients. Serum IGF-I levels and 
NK cell activity showed a positive correlation. IGF-I in vitro 
increased basal and IFN-/3 stimulated NK cell activity in normal 
subjects and in hGH-deficient adult patients. NK cell activity in 
GH deficiency might be decreased indirectly, because of lower 
serum levels of IGF-I. Recently, Watanabe et al. (15) suggested 
GH deficiency to be a risk factor for leukemia and hypothesized 
low NK cell activity to be a possible explanation for GH defi- 
ciency being related to the risk of leukemia. The role of NK cell 
activity in leukemia is not completely understood (26). In an 
attempt to elucidate a clinically important aspect of GH defi- 
ciency syndrome, further studies should focus on the relation- 
ship of GH deficiency, decreased NK cell activity, and the in- 
cidence of leukemia. 
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